Clinical utility of bone markers in various diseases
Abstract
No abstract availableKeywords
Funding Information
- Abbott Diagnostics
This publication has 175 references indexed in Scilit:
- Update on fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2012
- Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysisBone, 2012
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate CancerEuropean Urology, 2012
- Biochemical-markers for the diagnosis of bone metastasis: A clinical reviewCancer Epidemiology, 2012
- Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practiceBMC Musculoskeletal Disorders, 2011
- Bone structure and turnover in type 2 diabetes mellitusOsteoporosis International, 2011
- Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasisClinica Chimica Acta, 2010
- Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancerAnnals of Oncology, 2010
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006